Table 1.
Patient characteristics
| Variable | MMF 2mg n=93 N (%) |
MMF 3mg n=175 N (%) |
P-value* | |
|---|---|---|---|---|
| Age (years) | Median (range) | 52 (21–69) | 54 (18–72) | 0.18 |
| Male | 58 (62) | 105 (60) | 0.71 | |
| Year of HCT | <0.001 | |||
| 2000–2005 | 92 (99) | 4 (2) | ||
| 2006–2012 | 1 (1) | 171 (98) | ||
| HLA disparity (worst match) | <0.001 | |||
| 4/6 | 73 (78) | 82 (47) | ||
| 5/6 | 18 (19) | 79 (45) | ||
| 6/6 | 2 (2) | 14 (8) | ||
| ATG in conditioning | 29 (31) | 57 (33) | 0.82 | |
| Diagnosis | 0.24 | |||
| AML | 31 (33) | 73 (42) | ||
| MDS | 11 (12) | 31 (18) | ||
| CML | 6 (7) | 3 (2) | ||
| ALL | 9 (10) | 13 (7) | ||
| Lymphoma | 25 (27) | 42 (24) | ||
| CLL | 6 (7) | 7 (4) | ||
| Other† | 5 (5) | 6 (4) | ||
| Disease risk | 0.23 | |||
| Standard | 39 (42) | 87 (50) | ||
| High | 54 (58) | 88 (50) | ||
| HCT-CI | 0.60 | |||
| 0 | 20 (22) | 47 (27) | ||
| 1–2 | 25 (27) | 41 (23) | ||
| ≥ 3 | 42 (45) | 87 (50) | ||
| Missing | 6 (7) | 0 | ||
| CMV seropositive | 49 (53) | 109 (62) | 0.13 | |
| Total CD34 (×106/kg) | Median (range) | 0.5 (0.1–1.7) | 0.5 (0.1–3.5) | 0.24 |
| Weight (kg) | Median (range) | 78.2 (52.7–134.0) | 80.4 (43.7–142.3) | 0.47 |
| Body Mass Index | Median (range) | 26.7 (19.6–39.6) | 27.5 (17.2–45.0) | 0.20 |
| MMF (mg/kg) | Median (range) | 2.56 (1.49–3.80) | 3.73 (2.11–6.86) | <0.01 |
| 1st Quartile (<2.7) | 55 (59) | 32 (18) | <0.01 | |
| 2ndQuartile (2.7–3.2) | 29 (31) | 32 (18) | ||
| 3rd Quartile (3.2–3.9) | 9 (10) | 51 (29) | ||
| 4th Quartile (>3.9) | 0 | 60 (34) |
*
P-value for between-treatment comparisons. Continuous variables were analyzed by general Wilcoxon test. Categorical variables were analyzed by chi-square.
†
Other includes diagnoses of plasma cell disorders and biphenotypic leukemia